Which has better earnings & valuation, ORGO or CLNN?

Organogenesis has higher revenue and earnings than Clene. Organogenesis is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Organogenesis $564.17M 0.53 $37.03M -$0.19 N/A Clene $200K 368.06 -$26.17M -$3.20 N/A

Is ORGO or CLNN more profitable?

Organogenesis has a net margin of -0.84% compared to Clene's net margin of -25,009.70%. Organogenesis' return on equity of 9.63% beat Clene's return on equity. Company Net Margins Return on Equity Return on Assets Organogenesis -0.84% 9.63% 4.76% Clene -25,009.70% N/A -137.98%

Does the media prefer ORGO or CLNN?

In the previous week, Organogenesis had 1 more articles in the media than Clene. MarketBeat recorded 3 mentions for Organogenesis and 2 mentions for Clene. Organogenesis' average media sentiment score of 1.16 beat Clene's score of 0.93 indicating that Organogenesis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, PALI or CLNN?

Palisade Bio has higher revenue and earnings than Clene. Palisade Bio is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Palisade Bio $250K 1,340.04 -$16.78M -$1.01 N/A Clene $200K 368.06 -$26.17M -$3.20 N/A

Is PALI or CLNN more profitable?

Palisade Bio has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Palisade Bio's return on equity. Company Net Margins Return on Equity Return on Assets Palisade Bio N/A -36.79% -34.34% Clene -25,009.70% N/A -137.98%

Does the media refer more to PALI or CLNN?

In the previous week, Palisade Bio and Palisade Bio both had 2 articles in the media. Clene's average media sentiment score of 0.93 beat Palisade Bio's score of 0.63 indicating that Clene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate SIGA or CLNN?

Clene has a consensus target price of $33.25, suggesting a potential upside of 477.26%. Given Clene's stronger consensus rating and higher possible upside, analysts clearly believe Clene is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Clene 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has better valuation and earnings, SIGA or CLNN?

Siga Technologies has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Siga Technologies $94.57M 3.25 $23.28M $0.27 15.89 Clene $200K 368.06 -$26.17M -$3.20 N/A

Is SIGA or CLNN more profitable?

Siga Technologies has a net margin of 21.58% compared to Clene's net margin of -25,009.70%. Siga Technologies' return on equity of 10.60% beat Clene's return on equity. Company Net Margins Return on Equity Return on Assets Siga Technologies 21.58% 10.60% 8.94% Clene -25,009.70% N/A -137.98%

Is SOPH or CLNN more profitable?

SOPHiA GENETICS has a net margin of -44.48% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat SOPHiA GENETICS's return on equity. Company Net Margins Return on Equity Return on Assets SOPHiA GENETICS -44.48% -62.74% -21.85% Clene -25,009.70% N/A -137.98%

Does the media refer more to SOPH or CLNN?

In the previous week, SOPHiA GENETICS had 1 more articles in the media than Clene. MarketBeat recorded 3 mentions for SOPHiA GENETICS and 2 mentions for Clene. Clene's average media sentiment score of 0.93 beat SOPHiA GENETICS's score of 0.91 indicating that Clene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, CLNN or RGNX?

Clene has higher earnings, but lower revenue than REGENXBIO. Clene is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clene $200K 368.06 -$26.17M -$3.20 N/A REGENXBIO $170.44M 2.03 -$193.88M -$5.60 N/A

Is CLNN or RGNX more profitable?

REGENXBIO has a net margin of -330.23% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets Clene -25,009.70% N/A -137.98% REGENXBIO -330.23% -232.50% -61.02%

Does the media prefer CLNN or RGNX?

In the previous week, REGENXBIO had 2 more articles in the media than Clene. MarketBeat recorded 4 mentions for REGENXBIO and 2 mentions for Clene. Clene's average media sentiment score of 0.93 beat REGENXBIO's score of 0.64 indicating that Clene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Clene (CLNN) Competitors

$5.76 -0.11 (-1.87%)

Closing price 04:00 PM Eastern

Extended Trading

$5.70 -0.05 (-0.95%)

As of 07:58 PM Eastern

Compare

CLNN vs. ORGO, PALI, SIGA, SOPH, and RGNX

Should you buy Clene stock or one of its competitors? MarketBeat compares Clene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Clene include Organogenesis (ORGO), Palisade Bio (PALI), Siga Technologies (SIGA), SOPHiA GENETICS (SOPH), and REGENXBIO (RGNX). These companies are all part of the "pharmaceutical products" industry.

How does Clene compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 33.0% of Organogenesis shares are held by insiders. Comparatively, 28.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Organogenesis has a net margin of -0.84% compared to Clene's net margin of -25,009.70%. Organogenesis' return on equity of 9.63% beat Clene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-0.84%	9.63%	4.76%
Clene	-25,009.70%	N/A	-137.98%

Organogenesis has higher revenue and earnings than Clene. Organogenesis is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.53	$37.03M	-$0.19	N/A
Clene	$200K	368.06	-$26.17M	-$3.20	N/A

In the previous week, Organogenesis had 1 more articles in the media than Clene. MarketBeat recorded 3 mentions for Organogenesis and 2 mentions for Clene. Organogenesis' average media sentiment score of 1.16 beat Clene's score of 0.93 indicating that Organogenesis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Organogenesis	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organogenesis presently has a consensus target price of $5.75, indicating a potential upside of 146.78%. Clene has a consensus target price of $33.25, indicating a potential upside of 477.26%. Given Clene's stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Organogenesis has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Clene has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

Summary

Organogenesis beats Clene on 11 of the 16 factors compared between the two stocks.

How does Clene compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Palisade Bio presently has a consensus target price of $10.20, suggesting a potential upside of 428.50%. Clene has a consensus target price of $33.25, suggesting a potential upside of 477.26%. Given Clene's higher possible upside, analysts clearly believe Clene is more favorable than Palisade Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 28.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Palisade Bio has a net margin of 0.00% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
Clene	-25,009.70%	N/A	-137.98%

Palisade Bio has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Clene has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

In the previous week, Palisade Bio and Palisade Bio both had 2 articles in the media. Clene's average media sentiment score of 0.93 beat Palisade Bio's score of 0.63 indicating that Clene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Palisade Bio has higher revenue and earnings than Clene. Palisade Bio is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,340.04	-$16.78M	-$1.01	N/A
Clene	$200K	368.06	-$26.17M	-$3.20	N/A

Summary

Palisade Bio beats Clene on 9 of the 15 factors compared between the two stocks.

How does Clene compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Clene has a consensus target price of $33.25, suggesting a potential upside of 477.26%. Given Clene's stronger consensus rating and higher possible upside, analysts clearly believe Clene is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 2.7% of Siga Technologies shares are held by company insiders. Comparatively, 28.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Siga Technologies has a net margin of 21.58% compared to Clene's net margin of -25,009.70%. Siga Technologies' return on equity of 10.60% beat Clene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	21.58%	10.60%	8.94%
Clene	-25,009.70%	N/A	-137.98%

Siga Technologies has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Clene has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

In the previous week, Clene had 1 more articles in the media than Siga Technologies. MarketBeat recorded 2 mentions for Clene and 1 mentions for Siga Technologies. Siga Technologies' average media sentiment score of 1.89 beat Clene's score of 0.93 indicating that Siga Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Siga Technologies	Very Positive
Clene	Positive

Siga Technologies has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	3.25	$23.28M	$0.27	15.89
Clene	$200K	368.06	-$26.17M	-$3.20	N/A

Summary

Siga Technologies beats Clene on 9 of the 15 factors compared between the two stocks.

How does Clene compare to SOPHiA GENETICS?

SOPHiA GENETICS (NASDAQ:SOPH) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

SOPHiA GENETICS has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Clene has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

SOPHiA GENETICS presently has a consensus target price of $7.50, suggesting a potential upside of 56.90%. Clene has a consensus target price of $33.25, suggesting a potential upside of 477.26%. Given Clene's stronger consensus rating and higher probable upside, analysts clearly believe Clene is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SOPHiA GENETICS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by insiders. Comparatively, 28.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

SOPHiA GENETICS has a net margin of -44.48% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat SOPHiA GENETICS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SOPHiA GENETICS	-44.48%	-62.74%	-21.85%
Clene	-25,009.70%	N/A	-137.98%

In the previous week, SOPHiA GENETICS had 1 more articles in the media than Clene. MarketBeat recorded 3 mentions for SOPHiA GENETICS and 2 mentions for Clene. Clene's average media sentiment score of 0.93 beat SOPHiA GENETICS's score of 0.91 indicating that Clene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SOPHiA GENETICS	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Clene has lower revenue, but higher earnings than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Clene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SOPHiA GENETICS	$77.27M	4.24	-$79M	-$0.52	N/A
Clene	$200K	368.06	-$26.17M	-$3.20	N/A

Summary

Clene beats SOPHiA GENETICS on 9 of the 16 factors compared between the two stocks.

How does Clene compare to REGENXBIO?

Clene (NASDAQ:CLNN) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

REGENXBIO has a net margin of -330.23% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clene	-25,009.70%	N/A	-137.98%
REGENXBIO	-330.23%	-232.50%	-61.02%

23.3% of Clene shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 28.3% of Clene shares are owned by insiders. Comparatively, 14.2% of REGENXBIO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Clene presently has a consensus price target of $33.25, suggesting a potential upside of 477.26%. REGENXBIO has a consensus price target of $23.91, suggesting a potential upside of 257.39%. Given Clene's higher possible upside, equities research analysts clearly believe Clene is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, REGENXBIO had 2 more articles in the media than Clene. MarketBeat recorded 4 mentions for REGENXBIO and 2 mentions for Clene. Clene's average media sentiment score of 0.93 beat REGENXBIO's score of 0.64 indicating that Clene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Clene	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
REGENXBIO	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Clene has higher earnings, but lower revenue than REGENXBIO. Clene is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clene	$200K	368.06	-$26.17M	-$3.20	N/A
REGENXBIO	$170.44M	2.03	-$193.88M	-$5.60	N/A

Clene has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Summary

REGENXBIO beats Clene on 9 of the 16 factors compared between the two stocks.

Get Clene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLNN vs. The Competition

Export

Metric	Clene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$75.01M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-1.80	17.78	22.39	24.18
Price / Sales	368.06	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	-3.56	6.63	9.84	6.72
Net Income	-$26.17M	$24.20M	$3.57B	$337.19M
7 Day Performance	-13.90%	-3.24%	-1.16%	0.48%
1 Month Performance	-6.19%	0.53%	3.85%	5.07%
1 Year Performance	46.94%	47.24%	27.40%	34.25%

Clene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLNN Clene	3.6545 of 5 stars	$5.76 -1.9%	$33.25 +477.3%	+19.8%	$75.01M	$200K	N/A	100
ORGO Organogenesis	3.5056 of 5 stars	$2.66 flat	$8.50 +219.5%	-15.8%	$342.28M	$564.17M	N/A	950	Positive News
PALI Palisade Bio	1.6857 of 5 stars	$1.95 flat	$10.20 +423.1%	+144.7%	$338.48M	$250K	N/A	10
SIGA Siga Technologies	1.1552 of 5 stars	$4.68 flat	N/A	-28.9%	$335.67M	$94.57M	17.33	40	Positive News
SOPH SOPHiA GENETICS	2.3597 of 5 stars	$4.88 flat	$7.50 +53.7%	+69.8%	$334.21M	$77.27M	N/A	520

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLNN) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Clene (CLNN) Competitors